Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STOP-COPD Standard vs Targeted Oxygen Therapy Prehospital for Chronic Obstructive Pulmonary Disease
2022-502003-30-00Phase 4Authorised
- Sponsor
- Præhospitalet
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of oxygen, salbutamol, fenoterol and ipratropium bromide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by Præhospitalet. Primary endpoint: 30-day mortality. Planned start Dec 2022; status: authorised.
02
Drugs
oxygensalbutamolfenoterolipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2022-502003-30-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502003-30-00.